Skip to main content
European Commission logo
italiano italiano
CORDIS - Risultati della ricerca dell’UE
CORDIS
CORDIS Web 30th anniversary CORDIS Web 30th anniversary

ALGAE4IBD –FROM NATURE TO BEDSIDE- ALGAE BASED BIO COMPOUND FOR PREVENTION AND TREATMENT OF INFLAMMATION, PAIN AND IBD

Descrizione del progetto

Immergersi in profondità per scovare alghe antinfiammatorie

E se la soluzione alle malattie croniche si trovasse nei nostri oceani, fiumi o laghi? Il progetto Algae4IBD, finanziato dall’UE, risponderà a tale domanda. Grazie allo studio di composti di micro e macroalghe marine e di acqua dolce da prove pilota/di laboratorio alla commercializzazione, il progetto ricercherà in modo esaustivo mezzi per trasformare le risorse biologiche acquatiche naturali in composti attivi a livello biologico per la prevenzione e il trattamento della malattia infiammatoria cronica intestinale. In particolare, tale progetto svilupperà composti a base di alghe garantendo la conservazione della biodiversità tramite tecnologie all’avanguardia di estrazione e coltivazione. Algae4IBD propone soluzioni innovative per utilizzare in modo sostenibile i prodotti a base di alghe con una migliore qualità nutrizionale in modo da incidere positivamente in pazienti affetti da questa malattia.

Obiettivo

Algae4IBD's mission is to develop commercial products for Inflammatory Bowel Disease (IBD) prevention and treatment using aquatic natural biological resources. With the emerging developments in natural product, notable success has been achieved in discovering natural products and their synthetic structural analogues with anti-inflammatory activity. However, global biodiversity remains a largely unexploited resource for natural bioactive molecules with an enormous potential for developing commercial products with public health benefits. Micro and macroalgae, found in marine and freshwater, have been identified as promising sources of bioactive compounds including small molecules and secondary metabolites with a wide range of bioactivities as an antioxidant, anti-inflammatory and cancer preventive. Consumption of algae could, therefore, provide defence against chronic inflammatory diseases such as IBD, that until date have no effective cure. This project offers nature to bedside approach, using an entire development along the value chain for a new biodiscovery therapeutic approach by developing and examining algae-based compounds for IBD patients while guaranteeing algae's biodiversity preservation. We propose innovative solutions for increasing the use of algae-based ingredients and to ensure the science-based improvement of nutritional quality and its effect on public health. The researchers, companies and hospitals involved in the different stages of the project will use the biodiversity of algae, both micro and macro, as a wide source for bioactive compounds using state-of-the-art cultivation and extraction technologies for obtaining sufficient amounts of the bio-active molecules together with novel processing protocols. It will result in novel algal-based, high-quality bioactive compounds at GMP grade and lower costs for dual purposes – IBD prevention and treatment in relevance to the food as well as the pharmaceutical industries.

Invito a presentare proposte

H2020-FNR-2020

Vedi altri progetti per questo bando

Bando secondario

H2020-FNR-2020-2

Meccanismo di finanziamento

RIA - Research and Innovation action

Coordinatore

MIGAL GALILEE RESEARCH INSTITUTE LTD
Contribution nette de l'UE
€ 1 177 948,49
Indirizzo
SOUTH INDUSTRIAL ZONE
11016 KIRYAT SHEMONA
Israele

Mostra sulla mappa

Tipo di attività
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Collegamenti
Costo totale
€ 1 177 948,49

Partecipanti (23)